<qa>  What is the randomized phase IIIII trial?This randomized phase IIIII trial investigates the antileukemic activity and toxicity of the FLAG-Ida regimen as a second induction course in patients with acute myeloid leukaemia and bad response to the first induction cycle andor with a high risk karyotype and compares the antileukemic activity and toxicity of high dose cytarabinedaunorubicin vs. autologous peripheral blood stem cell transplantation as late consolidation therapy in standard risk patients. 